Ratings Sipai Health Technology Co., Ltd.

Equities

End-of-day quote Hong Kong S.E. Other stock markets 06:00:00 2024-05-22 pm EDT			5-day change	1st Jan Change
5.86 ^USD	-2.01%		-2.98%	-15.07%

Mar. 19	Sipai Health Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 05	Sipai Health Technology Expects to Narrow Loss in Full Year 2023	MT

With regards to fundamentals, the enterprise value to sales ratio is at 0.8 for the current period. Therefore, the company is undervalued.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

	1st Jan change	Capi.	ESG Refinitiv
SIPAI HEALTH TECHNOLOGY CO., LTD.	-15.07%	572M	-
WALGREENS BOOTS ALLIANCE, INC.	-38.91%	13.76B	B-
JD HEALTH INTERNATIONAL INC.	-31.33%	11.31B	B
ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED	-30.66%	6.32B	B
YIFENG PHARMACY CHAIN CO., LTD.	+15.73%	6.47B	C
MATSUKIYOCOCOKARA & CO.	-8.33%	6.09B	C+
CORPORATIVO FRAGUA, S.A.B. DE C.V.	+74.00%	4.95B	C
CLICKS GROUP LIMITED	-6.00%	3.95B	B
DASHENLIN PHARMACEUTICAL GROUP CO., LTD.	-14.62%	3.34B	C-
WELCIA HOLDINGS CO., LTD.	-12.02%	2.92B	C-

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality